Authors

Susana Pasión Fernández-Sánchez1, Berta Magallares-López2, Mª Concepción Uriel-Alonso1, Patricia Moya-Alvarado3, Carlos Paytubí-Garí4, Mª Àngels Sendra-Lluis1

Position

1Enfermera. Unidad de Reumatología y Enfermedades Autoinmunitarias Sistémicas. Hospital Universitario de la Santa Creu i Sant Pau. Barcelona2Licenciada en Medicina y Cirugía. Especialista en Reumatología. Unidad de Reumatología y Enfermedades Autoinmunitarias Sistémicas. Hospital Universitario de la Santa Creu i Sant Pau. Barcelona 3Doctora en Medicina. Especialista en Reumatología. Unidad de Reumatología y Enfermedades Autoinmunitarias Sistémicas. Hospital Universitario de la Santa Creu i Sant Pau. Barcelona4Licenciado en Medicina y Cirugía. Especialista en Medicina Interna. Departamento de Medicina Interna y Urgencias. Hospital General. Parc Sanitari de Sant Joan de Déu. Sant Boi de Llobregat (Barcelona)

Contact address

Susana Pasión Fernández Sánchez. C/ Gran vía de les Corts Catalanes, 1037. 08020 Barcelona.

Contact email: sfernandez@santpau.cat

Abstract

Objective: to determine the evolution in the rate of influenza and pneumococcal (23-valent) vaccination between the years 2010 and 2014 in rheumatic patients on treatment with immunosuppressants, and to evaluate the extent of documented respiratory infections within the year after vaccination.
Method: a retrospective cross-sectional descriptive study. Two hundred (200) patients were recruited by convenience sampling, with rheumatoid arthritis or spondyloarthropathy, on treatment with synthetic disease modifying antirheumatic drugs (DMARDs), biologic DMARDs or corticosteroids. Two arms of 100 patients were formed (2010 and 2014), and clinical records were reviewed in order to collect demographical variables, comorbidities, toxic habits, rheumatology diagnosis and years of disease evolution, treatment, administration of the influenza and the pneumococcal 23 vaccine, and number of respiratory infections during the following year.
Results: in the sample, 66% were women, their mean age was 66 years, with 12 years of disease evolution; 43.5% had received influenza vaccination, and 30% pneumococcal 23v vaccination; 21.5% presented respiratory infection within the time of follow-up. There was a higher rate of influenza and pneumococcal vaccination in 2014 vs. 2010 (49 and 29% vs. 38% and 21%, respectively); only the increase in pneumococcal coverage was statistically significant. Patients >65-year-old and with some comorbidity or toxic habit were more vaccinated (p< 0.05). There were no differences in vaccinations or in the number of respiratory infections based on the rheumatology diagnosis or the treatment received by the patient.
Conclusions: the vaccination rate improved in 2014 vs. 2010. However, the nursing professional must be involved in the improvement of the vaccination rate for these patients.

Keywords:

Vaccines; rheumatic disease; immunosuppressant treatment; infection; descriptive cross-sectional study; descriptive cross-sectional study

Versión en Español

Título:

Vacunación antigripal y antineumocócica 23 valencias en pacientes reumáticos en tratamiento con inmunosupresores